This section is intended for media and financial analysts
Search Press releases
20 Nov 2024
UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis
